HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

odiparcil

orally active beta-D-xyloside for the treatment of venous thrombosis in a rat model

Networked: 6 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycosides: 2119
  - odiparcil: 6

Experts

1.	Lacombe, Olivier: 3 articles (01/2022 - 01/2020)
2.	Tallandier, Mireille: 3 articles (01/2022 - 01/2020)
3.	Entchev, Eugeni: 2 articles (01/2022 - 01/2020)
4.	Jantzen, Ingrid: 2 articles (01/2022 - 01/2020)
5.	Abitbol, Jean-Louis: 1 article (01/2022)
6.	Antonelli, Sophie: 1 article (01/2022)
7.	Chowdary, Pratima: 1 article (01/2022)
8.	Cimbolini, Nicolas: 1 article (01/2022)
9.	Faudot-Vernier, Elodie: 1 article (01/2022)
10.	Feraille, Laurence: 1 article (01/2022)

Related Diseases

1.	Thrombosis (Thrombus) 09/01/2006 - "Odiparcil antithrombotic activity was limited by its mechanism to a maximum suppression of thrombus formation of 65-70%, and did not prolong bleeding indices. " 09/01/2006 - "Following oral dosing, warfarin and odiparcil produced dose-related suppression of thrombus formation. " 01/01/2006 - "Other agents in the early stages of development include several Xa inhibitors (LY-517717, YM150, DU-176b and apixaban [BMS-562247]), a factor IXa inhibitor (TTP889), and an orally active glycosaminoglycan enhancer (odiparcil [SB-424323]), which indirectly enhances thrombin inhibition via heparin cofactor II. Results have been reported from important, phase II dose-finding studies, and a number of registration-track phase III studies have been initiated, reflecting the drive towards potentially more effective, but primarily safer and more convenient therapies for the prevention and treatment of venous and arterial thrombosis. "
2.	Mucopolysaccharidosis VI (Syndrome, Maroteaux-Lamy) 01/01/2022 - "Oral treatment for mucopolysaccharidosis VI: Outcomes of the first phase IIa study with odiparcil." 01/01/2020 - "Here, we investigated the potential of the β-D-xyloside derivative odiparcil as an oral GAG clearance therapy for Maroteaux-Lamy syndrome (Mucopolysaccharidosis type VI, MPS VI). " 01/01/2020 - "Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models."
3.	Hemorrhage 10/01/2008 - "Odiparcil is a novel, orally active beta-d-thioxyloside analog with antithrombotic activity associated with a reduced risk of adverse bleeding events. " 09/01/2006 - "Odiparcil antithrombotic activity was limited by its mechanism to a maximum suppression of thrombus formation of 65-70%, and did not prolong bleeding indices. " 09/01/2006 - "In the following report, a new orally active beta-D-xyloside (odiparcil) has been characterized in a rat model of venous thrombosis and its efficacy and bleeding liability compared to warfarin. "
4.	Drug-Related Side Effects and Adverse Reactions 10/01/2008 - "Neither plasma GAG levels nor odiparcil plasma levels were correlated with a rise in hepatic transaminases, an adverse drug event observed in several subjects; and plasma odiparcil levels were indirectly correlated with plasma GAG levels. "
5.	Venous Thrombosis (Deep-Vein Thrombosis) 09/01/2006 - "A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis." 09/01/2006 - "In the following report, a new orally active beta-D-xyloside (odiparcil) has been characterized in a rat model of venous thrombosis and its efficacy and bleeding liability compared to warfarin. "

Related Drugs and Biologics

1.	Glycosaminoglycans
2.	Heparin Cofactor II
3.	Thrombin
4.	apixaban
5.	LY517717
6.	A-factor (Streptomyces)
7.	Warfarin (Coumadin)
8.	Transaminases (Aminotransferases)
9.	xylosides

Related Therapies and Procedures

1.	Therapeutics